Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diabetes drug could shield heart muscle during angioplasty

NCT ID NCT06342141

Disease control Sponsor: Instituto Nacional de Cardiologia Ignacio Chavez Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether empagliflozin (Jardiance), a diabetes drug, can reduce the 'no-reflow' phenomenon—when blood flow fails to fully restore after angioplasty—in 162 heart attack patients. Participants receive a loading dose before the procedure and daily doses for 3 days. The study measures blood flow, heart strain, and infarct size. It is active but not recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Empagliflozin (Jardiance)
What this could lead to
If it works, this could point toward a new way to prevent heart muscle damage during angioplasty for heart attacks.
What could go wrong
This is a small, early-phase trial (162 people) and the drug is already approved for diabetes, so the heart benefit is unproven. It may not reduce no-reflow or improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 162 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2024

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Acute myocardial infarction with ST-segment elevation * Presentation to the institute within 12 hours of symptom onset * Coronary angioplasty chosen as the reperfusion treatment for the subject * Known diagnosis of diabetes or admission glucose \>180 mg/dl. * Informed consent signed Exclusion Criteria: * Hemodynamically unstable subjects * Subjects undergoing thrombolysis treatment in the current event * History of coronary revascularization surgery * Known allergy or hypersensitivity to Sodium-glucose co-transporter-2 (SGLT2) inhibitors * History of recurrent urinary tract infections * Known chronic kidney disease and estimated glomerular filtration rate (eGFR) \< 20 * Ongoing treatment with any SGLT2 inhibitor * Participation in another clinical trial or having participated in the week prior to recruitment * For women of childbearing age: Current or planned pregnancy or lactation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for No-reflow phenomenon are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

No-Reflow Phenomenon ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

No-reflow phenomenon STEMI

Contacts and locations

Locations

  • National Institute of Cardiology

    Mexico City, Mexico City, 14080, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.